Latest Commercial Expansion News

Aroa Biosurgery delivered a breakout FY26 with NZ$104 million revenue, driven by strong Myriad sales and clinical trial success, setting the stage for ambitious FY27 growth.

Control Bionics has locked in $9.5 million through a discounted share placement, complemented by a $0.5 million Share Purchase Plan, to back its commercial growth and technology development.

Mesoblast has drawn US$50 million from a new five-year facility that reduces its interest burden and retires expensive short-term debt, strengthening its financial position ahead of commercial expansion.

CONNEQT Health has raised A$5.5 million through a two-tranche placement at a 15.4% discount, backed by key shareholders, to accelerate its commercial expansion and product development.

Wesfarmers outlines a bold growth and productivity agenda centred on AI integration, expanding retail footprints, and lithium project progress, underpinning strong shareholder returns and portfolio resilience.

LTR Pharma has secured a binding US telehealth commercialisation framework for its intranasal erectile dysfunction treatment ROXUS, committing to at least 150,000 prescriptions in the first year and granting exclusivity to Shed Holdings' platform.

EBR Systems has secured A$106.4 million through a fully underwritten institutional placement and entitlement offer, positioning the company for further commercial expansion of its wireless cardiac pacing technology.

ReNerve has inked an exclusive three-year deal with Hong Kong’s Swedish Trading Company to distribute its nerve repair products across a vast and dynamic healthcare region.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

Zoono Group has secured its first major commercial orders worth NZ$600,000 from Sharpak under an exclusive UK soft fruits packaging contract, marking a key step in scaling its antimicrobial coating technology in international markets.

Knosys has locked in a two-year, $3.8 million contract extension with ANZ, with full payment received upfront. This deal underpins Knosys’s role in ANZ’s AI integration efforts and strengthens the company’s cash position.

Memphasys has landed a major 1,000-cartridge order for its Felix™ System from MENA distributor ITL, with strong repeat demand from Qatar’s Hamad Medical Corporation and new market expansions into UAE, Kuwait, and soon Turkey.